Document Detail


Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity.
MedLine Citation:
PMID:  22270346     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: We implemented a retrospective study to explore discontinuation of therapy with adalimumab (ADA) without exacerbation in rheumatoid arthritis (RA) patients who had achieved low disease activity (LDA) with the biological agent.
METHODS: We enrolled 46 RA patients who had completed open extension of a double-blind, placebo-controlled trial of ADA monotherapy in Japan and who had LDA (DAS28-CRP <2.7) at the last administration of ADA in the extension trials; this date was defined as week 0 in the present study. Treatment of RA was at the discretion of the attending physician after week 0. The primary endpoint of this study was the percentage of patients who maintained discontinuation of biological agents and LDA for 52 weeks.
RESULTS: Twenty-four of the enrolled patients continued ADA while the rest discontinued ADA after the administration of the drug at week 0. Fourteen of the 22 patients did not restart biological agents, and 4 (18.2%) of these maintained LDA through week 52. All 4 of these patients had received ADA monotherapy before week 0.
CONCLUSION: Some RA patients who have achieved LDA with ADA monotherapy can discontinue the biologic without incurring increased disease activity. A prospective randomized study is required to confirm the results of our study.
Authors:
Masayoshi Harigai; Tsutomu Takeuchi; Yoshiya Tanaka; Tsukasa Matsubara; Hisashi Yamanaka; Nobuyuki Miyasaka
Related Documents :
19302946 - Mesial temporal sclerosis associated with methotrexate-induced leukoencephalopathy.
17371466 - Macroprolactinomas and epilepsy.
9106286 - Cranial mri findings in myotonic dystrophy.
8673506 - The running down phenomenon in temporal lobe epilepsy.
8831876 - Atrial fibrillation and stroke prevention in the community.
23253156 - Natural history of irritable bowel syndrome.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-01-20
Journal Detail:
Title:  Modern rheumatology / the Japan Rheumatism Association     Volume:  22     ISSN:  1439-7609     ISO Abbreviation:  Mod Rheumatol     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-15     Completed Date:  2013-05-07     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  100959226     Medline TA:  Mod Rheumatol     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  814-22     Citation Subset:  IM    
Affiliation:
Department of Pharmacovigilance, Tokyo Medical and Dental University, Yushima, Bunkyo-ku, Tokyo, Japan. mharigai.mpha@tmd.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antibodies, Monoclonal, Humanized / therapeutic use*
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / drug therapy*
Double-Blind Method
Female
Humans
Male
Middle Aged
Prospective Studies
Remission Induction
Severity of Illness Index
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 0/Antirheumatic Agents; FYS6T7F842/adalimumab
Comments/Corrections
Erratum In:
Mod Rheumatol. 2012 Nov;22(6):823

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  NEFA/nucleobindin-2 is a target autoantigen of the anti-Wa antibody and is associated with transfer ...
Next Document:  A case of adult-onset Still's disease (AOSD)-like manifestations abruptly developing during confirma...